CIK 0001468929 · <br>Emerging growth company
NEXGEL, INC.
Sign in to watch- Ticker
- NXGL
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 264042544
- Phone
- 215 702-8550
- Business address
- 2150 CABOT BLVD WEST,, SUITE B, LANGHORNE, PA, 19047
- Former names
- NEXGEL, INC., AquaMed Technologies, Inc.
Securities
- NXGL Common Stock Nasdaq
- NXGLW Warrant Nasdaq
- 4 Planned sale Director sold 7,697 shares at $2.36 ($18,149)
- 4 Open-market sale Chief Executive Officer sold 4,000 shares at $2.47 ($9,896)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Director sold 3,000 shares at $2.57 ($7,704)
- 4 Open-market sale Chief Executive Officer sold 4,000 shares at an average $2.36 ($9,439)
- 4 Open-market sale Chief Executive Officer sold 2,000 shares at an average $2.31 ($4,613)
- 4 Open-market sale Chief Executive Officer sold 1,000 shares at $2.22 ($2,220)
- 4 Open-market sale Chief Executive Officer sold 1,000 shares at $2.58 ($2,575)
- 4 Planned sale Director sold 3,000 shares at $2.69 ($8,062)
- 4 Planned sale Director sold 3,000 shares at $2.61 ($7,825)
- 4 Planned sale Chief Executive Officer sold 4,000 shares at $3.01 ($12,038)
- 4 Planned sale Director sold 3,000 shares at $2.87 ($8,621)
- 4 Planned sale Chief Executive Officer sold 4,000 shares at $3.16 ($12,639)
- 4 Grant or award Director acquired 2,500 shares (grant or award)
- 4 Planned sale Director sold 3,000 shares at $3.27 ($9,798)
- 4 Planned sale Chief Executive Officer sold 4,000 shares at $3.64 ($14,558)
Page 2 of 6 · 115 filings